Brian G Weinshenker

List of Publications by Citations

207 papers	37,153 citations	69 h-index	192 g-index
230 ext. papers	43,916 ext. citations	8.3 avg, IF	7.04 L-index

#	Paper	IF	Citations
207	Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Annals of Neurology*, **2011**, 69, 292-302	9.4	6480
206	Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". *Annals of Neurology*, **2005**, 58, 840-6	9.4	4020
205	Multiple sclerosis. *New England Journal of Medicine*, **2000**, 343, 938-52	59.2	2821
204	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurology, The*, **2018** , 17, 162-173	24.1	2419
203	A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. *Lancet, The*, **2004**, 364, 2106-12	40	2296
202	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology*, **2015**, 85, 177-89	6.5	2255
201	The spectrum of neuromyelitis optica. *Lancet Neurology, The*, **2007**, 6, 805-15	24.1	1584
200	A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. *Brain*, **2002**, 125, 1450-61	11.2	825
199	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. *Annals of Neurology*, **1999**, 46, 878-86	9.4	682
198	Brain abnormalities in neuromyelitis optica. *Archives of Neurology*, **2006**, 63, 390-6		563
197	Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. *Archives of Neurology*, **2006**, 63, 964-8		560
196	Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. *Brain*, **2007**, 130, 1194-205	11.2	556
195	Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. *Annals of Neurology*, **2006**, 59, 566-9	9.4	474
194	Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. *Scientific Reports*, **2016**, 6, 28484	4.9	437
193	Neuromyelitis optica and non organ-specific autoimmunity. *Archives of Neurology*, **2008**, 65, 78-83		387
192	Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. *Archives of Neurology*, **2008**, 65, 1443-8		376
191	Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. *Neurology*, **2004**, 63, 1788-95	6.5	356

190	Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. *Lancet, The*, **2005**, 366, 579-82	40	355
189	Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. *Lancet Neurology, The*, **2013**, 12, 554-62	24.1	278
188	Neuromyelitis optica: clinical predictors of a relapsing course and survival. *Neurology*, **2003**, 60, 848-53	6.5	264
187	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. *Lancet, The*, **2019**, 394, 1352-1363	40	247
186	Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). *Brain*, **2010**, 133, 2626-34	11.2	232
185	Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. *Archives of Neurology*, **2009**, 66, 1128-33		229
184	Natural history of multiple sclerosis. *Annals of Neurology*, **1994**, 36 Suppl, S6-11	9.4	228
183	Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. *Annals of Neurology*, **2017**, 81, 298-309	9.4	200
182	The investigation of acute optic neuritis: a review and proposed protocol. *Nature Reviews Neurology*, **2014**, 10, 447-58	15	188
181	Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. *Annals of Neurology*, **2004**, 56, 303-6	9.4	183
180	Treatment of Neuromyelitis Optica: Review and Recommendations. *Multiple Sclerosis and Related Disorders*, **2012**, 1, 180-187	4	176
179	Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. *Annals of Neurology*, **2016**, 79, 775-783	9.4	173
178	Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. *American Journal of Ophthalmology*, **2018**, 195, 8-15	4.9	171
177	A point mutation in PTPRC is associated with the development of multiple sclerosis. *Nature Genetics*, **2000**, 26, 495-9	36.3	170
176	An approach to the diagnosis of acute transverse myelitis. *Seminars in Neurology*, **2008**, 28, 105-20	3.2	169
175	Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. *JAMA Neurology*, **2015**, 72, 81-7	17.2	162
174	Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. *JAMA Neurology*, **2018**, 75, 1355-1363	17.2	159
173	The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. *Multiple Sclerosis Journal*, **2012**, 18, 5-10	5	157

172	Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. *Neurology*, **2013**, 81, 1197-204	6.5	157
171	Neuromyelitis Spectrum Disorders. *Mayo Clinic Proceedings*, **2017**, 92, 663-679	6.4	153
170	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. *Brain*, **2019**, 142, 1858-1875	11.2	150
169	The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. *Neurology*, **2016**, 87, 1393-9	6.5	150
168	Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 188-98	5	148
167	Beneficial plasma exchange response in central nervous system inflammatory demyelination. *Archives of Neurology*, **2011**, 68, 870-8		145
166	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. *JAMA Neurology*, **2019**, 76, 301-309	17.2	141
165	Intractable vomiting as the initial presentation of neuromyelitis optica. *Annals of Neurology*, **2010**, 68, 757-61	9.4	139
164	Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. *Lancet Neurology, The*, **2020**, 19, 402-412	24.1	137
163	Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. *Brain*, **2010**, 133, 333-48	11.2	134
162	Neuromyelitis optica. *Current Treatment Options in Neurology*, **2008**, 10, 55-66	4.4	113
161	Acute disseminated encephalomyelitis: current understanding and controversies. *Seminars in Neurology*, **2008**, 28, 84-94	3.2	111
160	Disease modifying therapies for relapsing multiple sclerosis. *BMJ, The*, **2016**, 354, i3518	5.9	109
159	Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. *Muscle and Nerve*, **2009**, 39, 87-90	3.4	104
158	Discriminating long myelitis of neuromyelitis optica from sarcoidosis. *Annals of Neurology*, **2016**, 79, 437-47	9.4	102
157	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. *Frontiers in Neurology*, **2020**, 11, 501	4.1	93
156	Natural history of multiple sclerosis. *Neurologic Clinics*, **2005**, 23, 17-38, v	4.5	93
155	The natural history of recurrent optic neuritis. *Archives of Neurology*, **2004**, 61, 1401-5		91

154	Neuromyelitis optica: changing concepts. *Journal of Neuroimmunology*, **2007**, 187, 126-38	3.5	90
153	Atypical inflammatory demyelinating syndromes of the CNS. *Lancet Neurology, The*, **2016**, 15, 967-981	24.1	86
152	Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD. *Neurology*, **2018**, 91, e1642-e1651	6.5	84
151	Neuromyelitis Optica. *Current Treatment Options in Neurology*, **2005**, 7, 173-182	4.4	80
150	Update on biomarkers in neuromyelitis optica. *Neurology: Neuroimmunology and NeuroInflammation*, **2015**, 2, e134	9.1	79
149	Neuromyelitis optica. *Nature Reviews Disease Primers*, **2020**, 6, 85	51.1	77
148	Evaluation of aquaporin-4 antibody assays. *Clinical and Experimental Neuroimmunology*, **2014**, 5, 290-303	0.4	76
147	Neuromyelitis optica. *Current Opinion in Neurology*, **2007**, 20, 255-60	7.1	76
146	Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. *Brain*, **2019**, 142, 1310-1323	11.2	75
145	Relapses and disability accumulation in progressive multiple sclerosis. *Neurology*, **2015**, 84, 81-8	6.5	75
144	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. *Lancet Neurology, The*, **2019**, 18, 185-197	24.1	74
143	Neuromyelitis optica: what it is and what it might be. *Lancet, The*, **2003**, 361, 889-90	40	73
142	Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. *Archives of Neurology*, **2009**, 66, 1134-8		72
141	NMO-IgG: a specific biomarker for neuromyelitis optica. *Disease Markers*, **2006**, 22, 197-206	3.2	70
140	Characteristics of Spontaneous Spinal Cord Infarction and Proposed Diagnostic Criteria. *JAMA Neurology*, **2019**, 76, 56-63	17.2	70
139	Neuromyelitis optica is distinct from multiple sclerosis. *Archives of Neurology*, **2007**, 64, 899-901		69
138	Effects of age and sex on aquaporin-4 autoimmunity. *Archives of Neurology*, **2012**, 69, 1039-43		67
137	The natural history of multiple sclerosis: update 1998. *Seminars in Neurology*, **1998**, 18, 301-7	3.2	67

136	Screening for major depression in the early stages of multiple sclerosis. *Canadian Journal of Neurological Sciences*, **1995**, 22, 228-31	1	66
135	Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. *Neurology*, **2015**, 85, 722-9	6.5	65
134	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. *Neurology*, **2020**, 95, e111-e120	6.5	65
133	Central canal enhancement and the trident sign in spinal cord sarcoidosis. *Neurology*, **2016**, 87, 743-4	6.5	64
132	OSMS is NMO, but not MS: proven clinically and pathologically. *Lancet Neurology, The*, **2006**, 5, 110-1	24.1	63
131	Specific pattern of gadolinium enhancement in spondylotic myelopathy. *Annals of Neurology*, **2014**, 76, 54-65	9.4	61
130	Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention. *Current Neurology and Neuroscience Reports*, **2013**, 13, 403	6.6	61
129	Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. *Ophthalmology*, **2018**, 125, 1628-1637	7.3	59
128	Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica. *JAMA Neurology*, **2013**, 70, 1118-25	17.2	52
127	Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. *Multiple Sclerosis Journal*, **2016**, 22, 862-72	5	51
126	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology*, **2016**, 86, 491-2	6.5	51
125	Cerebrospinal Fluid Oligoclonal Bands in the Diagnosis of Multiple Sclerosis. *American Journal of Clinical Pathology*, **2003**, 120, 672-675	1.9	49
124	Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion. *Neurology*, **2016**, 87, 1713-1719	6.5	47
123	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. *Multiple Sclerosis and Related Disorders*, **2020**, 44, 102251	4	46
122	Longitudinally extensive transverse myelitis. *Current Opinion in Neurology*, **2014**, 27, 279-89	7.1	45
121	Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. *JAMA Neurology*, **2014**, 71, 48-54	17.2	44
120	Cervical spinal cord atrophy: An early marker of progressive MS onset. *Neurology: Neuroimmunology and NeuroInflammation*, **2018**, 5, e435	9.1	43
119	Intractable nausea and vomiting from autoantibodies against a brain water channel. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 240-5	6.9	43

118	Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 218-225	5.5	40
117	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. *Journal of Neurology*, **2016**, 263, 140-9	5.5	40
116	Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	40
115	Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. *Neurology*, **2015**, 84, 148-58	6.5	39
114	High risk of postpartum relapses in neuromyelitis optica spectrum disorder. *Neurology*, **2017**, 89, 2238-2244	6.5	38
113	Neuromyelitis optica (Devic© syndrome). *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2014**, 122, 581-99	3	38
112	Approach to acute or subacute myelopathy. *Neurology*, **2010**, 75, S2-8	6.5	38
111	Elsberg syndrome: A rarely recognized cause of cauda equina syndrome and lower thoracic myelitis. *Neurology: Neuroimmunology and NeuroInflammation*, **2017**, 4, e355	9.1	37
110	Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. *JAMA Neurology*, **2020**, 77, 937-946	17.2	37
109	Myelin-oligodendrocyte glycoprotein antibody-associated disease. *Lancet Neurology, The*, **2021**, 20, 762-772	44.1	37
108	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. *Neurology: Neuroimmunology and NeuroInflammation*, **2017**, 4, e343	9.1	36
107	Familial chordoma with probable autosomal dominant inheritance. *American Journal of Medical Genetics Part A*, **1998**, 75, 335-6		36
106	Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. *Journal of Clinical Apheresis*, **2001**, 16, 39-42	3.2	36
105	Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event. *Annals of Neurology*, **2020**, 88, 407-417	9.4	35
104	Neuromyelitis optica spectrum disorders. *Current Neurology and Neuroscience Reports*, **2014**, 14, 483	6.6	35
103	Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. *Journal of Clinical Apheresis*, **1999**, 14, 144-8	3.2	34
102	Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 488-490	5.5	33
101	Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. *Neurology*, **2012**, 78, 540-4	6.5	32

100	Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. *International Journal of Radiation Oncology Biology Physics*, **2006**, 66, 1178-86	4	31
99	Challenges and opportunities in designing clinical trials for neuromyelitis optica. *Neurology*, **2015**, 84, 1805-15	6.5	30
98	Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis. *Journal of Clinical Apheresis*, **1995**, 10, 163-70	3.2	30
97	Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study. *Multiple Sclerosis Journal*, **2018**, 24, 331-339	5	29
96	Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica. *Archives of Neurology*, **2011**, 68, 953-5		28
95	Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management. *Multiple Sclerosis Journal*, **2017**, 23, 1808-1817	5	27
94	Interferon gamma allelic variants: sex-biased multiple sclerosis susceptibility and gene expression. *Archives of Neurology*, **2008**, 65, 349-57		27
93	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. *Multiple Sclerosis Journal*, **2021**, 27, 303-308	5	25
92	Compressive myelopathy mimicking transverse myelitis. *Neurologist*, **2010**, 16, 120-2	1.6	24
91	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. *Annals of Neurology*, **2021**, 89, 895-910	9.4	23
90	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. *JAMA Neurology*, **2021**, 78, 741-746	17.2	23
89	A Clinical Approach to the Differential Diagnosis of Multiple Sclerosis. *Current Neurology and Neuroscience Reports*, **2015**, 15, 57	6.6	22
88	Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. *Archives of Neurology*, **2009**, 66, 964-6		21
87	Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. *Neurology: Neuroimmunology and NeuroInflammation*, **2017**, 4, e339	9.1	20
86	The frequency of longitudinally extensive transverse myelitis in MS: A population-based study. *Multiple Sclerosis and Related Disorders*, **2020**, 37, 101487	4	20
85	Optic neuritis in an ethnically diverse population: higher risk of atypical cases in patients of African or African-Caribbean heritage. *Journal of the Neurological Sciences*, **2012**, 312, 21-5	3.2	19
84	Corticosteroid-Induced Paraplegia: A Diagnostic Clue for Spinal Dural Arterial Venous Fistula. *JAMA Neurology*, **2015**, 72, 833-4	17.2	18
83	Hydrocephalus in neuromyelitis optica. *Neurology*, **2014**, 82, 1841-3	6.5	18

82	HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica. *Multiple Sclerosis Journal*, **2010**, 16, 981-4	5	18
81	Optic Disc Edema in Glial Fibrillary Acidic Protein Autoantibody-Positive Meningoencephalitis. *Journal of Neuro-Ophthalmology*, **2018**, 38, 276-281	2.6	18
80	Spinal cord infarction: Clinical and imaging insights from the periprocedural setting. *Journal of the Neurological Sciences*, **2018**, 388, 162-167	3.2	17
79	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. *Neurology*, **2021**, 97, e1097-e1109	6.5	17
78	ACUTE LEUKOENCEPHALOPATHIES. *Neurologist*, **1998**, 4, 148-166	1.6	16
77	Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)?. *Neurology*, **2020**, 94, 85-88	6.5	15
76	Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy. *Neurology: Clinical Practice*, **2015**, 5, 175-177	1.7	14
75	Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7, e727	9.1	14
74	Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. *Neurology*, **2019**, 93, e414-e420	6.5	14
73	Ball□oncentric sclerosis evolving from apparent tumefactive demyelination. *Neurology*, **2017**, 88, 2150-2152	6.5	13
72	Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria. *Multiple Sclerosis Journal*, **2021**, 27, 250-258	5	13
71	Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis. *JAMA Neurology*, **2018**, 75, 892-895	17.2	13
70	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**,	5.5	13
69	Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS. *Neurology*, **2018**, 90, 1106-1112	6.5	12
68	Pregnancy outcomes in a woman with neuromyelitis optica. *Neurology*, **2014**, 83, 1576-7	6.5	12
67	Acute disseminated encephalomyelitis, transverse myelitis, and neuromyelitis optica. *CONTINUUM Lifelong Learning in Neurology*, **2013**, 19, 944-67	3	12
66	Occurrence of CNS demyelinating disease in patients with myasthenia gravis. *Neurology*, **2007**, 68, 1326; author reply 1327	6.5	12
65	Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease. *Multiple Sclerosis Journal*, **2018**, 24, 1445-1452	5	11

64	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review. *JAMA Neurology*, **2021**, 78, 351-364	17.2	11
63	Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia. *Multiple Sclerosis and Related Disorders*, **2019**, 36, 101413	4	10
62	Unilateral motor progression in MS: Association with a critical corticospinal tract lesion. *Neurology*, **2019**, 93, e628-e634	6.5	10
61	Tumefactive demyelinating lesions: Characteristics of individual lesions, individual patients, or a unique disease entity?. *Multiple Sclerosis Journal*, **2015**, 21, 1746-7	5	9
60	Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials. *Nature Reviews Neurology*, **2021**, 17, 759-773	15	9
59	Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD. *Multiple Sclerosis Journal*, **2021**, 27, 630-635	5	9
58	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. *Neurology*, **2021**, 97, e1351-e1358	6.5	9
57	Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS - NO. *Multiple Sclerosis Journal*, **2017**, 23, 1190-1192	5	8
56	Acute demyelinating disorders: emergencies and management. *Neurologic Clinics*, **2012**, 30, 285-307, ix-x	4.5	8
55	Teaching neuroimages: "pancake-like" gadolinium enhancement suggests compressive myelopathy due to spondylosis. *Neurology*, **2013**, 80, e229	6.5	8
54	Anterior spinal artery infarction causing man-in-the-barrel syndrome. *Neurology: Clinical Practice*, **2014**, 4, 268-269	1.7	7
53	Association of IL2RA polymorphisms with susceptibility to multiple sclerosis is not explained by missense mutations in IL2RA. *Multiple Sclerosis Journal*, **2011**, 17, 634-6	5	7
52	Gait apraxia in multiple sclerosis. *Canadian Journal of Neurological Sciences*, **2009**, 36, 562-5	1	7
51	Reproductive history and progressive multiple sclerosis risk in women. *Brain Communications*, **2020**, 2, fcaa185	4.5	7
50	What Is the Optimal Sequence of Rescue Treatments for Attacks of Neuromyelitis Optica Spectrum Disorder?. *Annals of Neurology*, **2016**, 79, 204-5	9.4	7
49	Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders. *JAMA Neurology*, **2020**, 77, 1572-1575	17.2	6
48	MOG-IgG1 and co-existence of neuronal autoantibodies. *Multiple Sclerosis Journal*, **2021**, 27, 1175-1186	5	6
47	Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. *Neurology: Neuroimmunology and NeuroInflammation*, **2021**, 8,	9.1	6

46	Simultaneous PML-IRIS and myelitis in a patient with neuromyelitis optica spectrum disorder. *Neurology: Clinical Practice*, **2013**, 3, 448-451	1.7	5
45	Lupus related longitudinal myelitis. *Journal of Rheumatology*, **2011**, 38, 1520; author reply 1521	4.1	5
44	Laquinimod, a new oral drug for multiple sclerosis. *Lancet, The*, **2008**, 371, 2059-60	40	5
43	Pediatric familial neuromyelitis optica in two sisters with long term follow-up. *Journal of Clinical Neuroscience*, **2016**, 29, 183-4	2.2	5
42	Utility of MRI Enhancement Pattern in Myelopathies With Longitudinally Extensive T2 Lesions. *Neurology: Clinical Practice*, **2021**, 11, e601-e611	1.7	5
41	McArdle Sign: A Specific Sign of Multiple Sclerosis. *Mayo Clinic Proceedings*, **2019**, 94, 1427-1435	6.4	4
40	Teaching neuroimages: MRI in advanced neuromyelitis optica. *Neurology*, **2014**, 82, e101-2	6.5	4
39	Relapsing inappropriate antidiuretic hormone secretion in an anti-aquaporin-4 antibody positive paediatric patient. *Multiple Sclerosis Journal*, **2014**, 20, 1404-6	5	4
38	Japanese optic-spinal MS: is it MS or neuromyelitis optica and does the answer dictate treatment?. *Neurology*, **2010**, 75, 1404-5	6.5	4
37	Asymptomatic spinal cord involvement in posterior reversible encephalopathy syndrome. *Neurology*, **2010**, 74, 1478-9; author reply 1479	6.5	4
36	More on Multiple Sclerosis and Neuromyelitis Optica—Reply. *Archives of Neurology*, **2007**, 64, 1802		4
35	Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States. *Multiple Sclerosis Journal*, **2021**, 13524585211048401	5	4
34	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. *Multiple Sclerosis Journal*, **2021**, 27, 2052-2061	5	4
33	Population-based study of "no evident disease activity" in MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2018**, 5, e495	9.1	4
32	CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis. *Mayo Clinic Proceedings*, **2021**,	6.4	4
31	Neuromyelitis Optica. *Blue Books of Neurology*, **2010**, 35, 258-275		3
30	Neuromyelitis Optica and Autoimmune Diseases—Reply. *Archives of Neurology*, **2008**, 65, 992		3
29	Testing for Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG) in typical MS. *Multiple Sclerosis and Related Disorders*, **2019**, 35, 34-35	4	2

28	Clinical spectrum of neuromyelitis optica 2013. *Neurology and Clinical Neuroscience*, **2014**, 2, 23-27	0.3	2
27	Placebo Studies should not be Undertaken in Neuromyelitis Optica: Commentary. *Multiple Sclerosis Journal*, **2015**, 21, 693-4	5	2
26	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.. *Multiple Sclerosis and Related Disorders*, **2022**, 57, 103356	4	2
25	Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. *Multiple Sclerosis Journal*, **2021**, 27, 667-673	5	2
24	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease **1999**, 46, 878		2
23	Teaching NeuroImages: Primary Sjgren syndrome presenting as isolated lesion of medulla oblongata. *Neurology*, **2015**, 85, 204-5	6.5	1
22	Christian Confavreux (1949 - 2013). *Multiple Sclerosis Journal*, **2013**, 19, 1811-2	5	1
21	Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: no. *Multiple Sclerosis Journal*, **2012**, 18, 1211-2	5	1
20	Plasmapheresis: are bigger studies necessarily better?. *Nature Reviews Neurology*, **2012**, 8, 410; author reply 410	15	1
19	Re: Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther. 2003;25:105-118. *Clinical Therapeutics*, **2003**, 25, 1888-90	3.5	1
18	Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2021**, 7, 20552173211052656	2	1
17	Confirming a Historical Diagnosis of Multiple Sclerosis: Challenges and Recommendations. *Neurology: Clinical Practice*,10.1212/CPJ.0000000000001149	1.7	1
16	Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis. *Multiple Sclerosis Journal*, **2019**, 25, 709-714	5	1
15	Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. *Multiple Sclerosis Journal*, **2021**, 27, 895-902	5	1
14	Inflammatory activity following motor progression due to critical CNS demyelinating lesions. *Multiple Sclerosis Journal*, **2021**, 27, 1037-1045	5	1
13	Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system **1999**, 14, 144		1
12	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.. *Multiple Sclerosis Journal*, **2022**, 13524585211069068	5	1
11	Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2021**, 7, 20552173211048761	2	0

10	Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions.. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2022**, 8, 20552173211052159	2	0
9	Biomechanical muscle stiffness measures of extensor digitorum explain potential mechanism of McArdle sign. *Clinical Biomechanics*, **2021**, 82, 105277	2.2	0
8	Author response: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. *Neurology*, **2017**, 88, 2067-2068	6.5	
7	EXPERT OPINIONS ON THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH AQP4-NEGATIVE NMO/MS OVERLAPPING SYNDROMES. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, e4.40-e4	5.5	
6	Neuromyelitis Optica **2014**, 153-162		
5	Posterior reversible encephalopathy syndrome is not associated with mutations in aquaporin-4. *Neurology: Genetics*, **2015**, 1, e19	3.8	
4	Spinal Cord Compression and Myelopathies **2012**, 235-257		
3	Do old HLA and mitochondrial DNA variants associate with demyelination types in young patients?. *Neurology*, **2011**, 76, 768-9	6.5	
2	Vessel Wall Enhancement in Unilateral Primary Angiitis of the Central Nervous System. *Canadian Journal of Neurological Sciences*, **2021**, 1-3	1	
1	Spinal Cord Compression and Myelopathies **2021**, 251-278		